Craig-Hallum initiated coverage of Compass Therapeutics (CMPX) with a Buy rating and $15 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMPX:
- Compass Therapeutics price target raised to $13 from $10 at Canaccord
- Compass Therapeutics: Strengthening Clinical Pipeline and 2026 Milestones Underscore Buy Rating and Upside Potential
- Compass Therapeutics: Strong Cash Position and 2026 Clinical Catalysts Underpin Reiterated Buy Rating
- Compass Therapeutics provides corporate update
- Compass Therapeutics details cash runway and pipeline progress